Last reviewed · How we verify
cholecalciferol and calcium carbonate
Cholecalciferol and calcium carbonate, marketed by the Indian Council of Medical Research, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of reported revenue data, which may limit investor confidence and strategic planning.
At a glance
| Generic name | cholecalciferol and calcium carbonate |
|---|---|
| Also known as | vitamin D and calcium carbonate, calcium carbonate |
| Sponsor | Indian Council of Medical Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (PHASE4)
- Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis (NA)
- Efect Supplementation Vitamin D in Diabetes Mellitus Type 2 (NA)
- Effect of Oral Vitamin D3 and Calcium Supplementation on Muscle and Bone Health Among Rural Post-menopausal Women (NA)
- The Effect of Aerobic Exercise on Bone Turnover Markers in Postmenopausal Patients (NA)
- Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial (NA)
- Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: